Literature DB >> 12849203

Approval of alteplase in Europe: will it change stroke management?

Markku Kaste1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12849203     DOI: 10.1016/s1474-4422(03)00343-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

1.  Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion.

Authors:  M Arnold; U Koerner; L Remonda; K Nedeltchev; H P Mattle; G Schroth; M Sturzenegger; J Weber; F Koerner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 2.  Therapeutic time window of thrombolytic therapy following stroke.

Authors:  Peter D Schellinger; Steven Warach
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

Review 3.  The economic burden of stroke: a systematic review of cost of illness studies.

Authors:  Stefan Strilciuc; Diana Alecsandra Grad; Constantin Radu; Diana Chira; Adina Stan; Marius Ungureanu; Adrian Gheorghe; Fior-Dafin Muresanu
Journal:  J Med Life       Date:  2021 Sep-Oct

4.  Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.

Authors:  Peter Sandercock; Richard Lindley; Joanna Wardlaw; Martin Dennis; Steff Lewis; Graham Venables; Adam Kobayashi; Anna Czlonkowska; Eivind Berge; Karsten Bruins Slot; Veronica Murray; Andre Peeters; Graeme Hankey; Karl Matz; Michael Brainin; Stefano Ricci; Maria Grazia Celani; Enrico Righetti; Teresa Cantisani; Gord Gubitz; Steve Phillips; Antonio Arauz; Kameshwar Prasad; Manuel Correia; Phillippe Lyrer
Journal:  Trials       Date:  2008-06-17       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.